Back to today’s briefing

Story perspectives

New Treatment Shows Promise for NF1-Mutant Melanoma

6/12/2025

26 6

Summary

Story summary

Researchers at NYU Langone Health have discovered a promising treatment for melanoma patients with neurofibromin 1 (NF1) mutations, who typically resist immunotherapy. Their study revealed that EGFR inhibitors, such as cetuximab and afatinib, significantly slowed tumor growth in NF1-mutant models. Exciting clinical trials are on the horizon to evaluate these drugs' safety and effectiveness.

1 of 1

Story summary

Researchers at NYU Langone Health have discovered a promising treatment for melanoma patients with neurofibromin 1 (NF1) mutations, who typically resist immunotherapy. Their study revealed that EGFR inhibitors, such as cetuximab and afatinib, significantly slowed tumor growth in NF1-mutant models. Exciting clinical trials are on the horizon to evaluate these drugs' safety and effectiveness.